Company intelligence / Profile preview

BLUEPEN GROUP

Murrieta, California, USAin.linkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

BluePen Biomarkers offers an integrated multi-omics biomarker discovery and validation service/platform. It quantifies and analyzes genomics, proteomics, metabolomics, lipidomics data alongside clinical/demographic information. The technology enables identification of diagnostic/prognostic/treatment-response biomarkers for research through clinical trials. The company’s approach allows for surrogate marker identification from different modalities for less invasive testing with high predictive value. No direct drug or diagnostic product approvals reported.

Therapeutic areas: Oncology
Modalities: Diagnostic platform (multi-omics biomarker discovery and validation)Not a therapeutic developer; does not develop drugs directly
Industry: Drug Discovery Services

Partnerships

Blueprint Bio (co-founder/commercialization partner)Emerald Logic (data analytics partner)

Beyond the preview

Go deeper on BLUEPEN GROUP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLUEPEN GROUP.

Explore the full profile